Deregulated expression of miR‐107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin‐1 and PTEN

[1]  D. Ichikawa,et al.  Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer , 2017, Scientific Reports.

[2]  Yunfeng Fu,et al.  miR-107 Promotes Proliferation and Inhibits Apoptosis of Colon Cancer Cells by Targeting Prostate Apoptosis Response-4 (Par4) , 2017, Oncology research.

[3]  Gang Zhang,et al.  MicroRNA‐107 is downregulated and having tumor suppressive effect in breast cancer by negatively regulating brain‐derived neurotrophic factor , 2016, The journal of gene medicine.

[4]  Jianwei Zhou,et al.  miR-107 regulates tumor progression by targeting NF1 in gastric cancer , 2016, Scientific Reports.

[5]  Xiaozhou He,et al.  LncRNA GAS5 inhibits proliferation and progression of prostate cancer by targeting miR-103 through AKT/mTOR signaling pathway , 2016, Tumor Biology.

[6]  Junxia Chen,et al.  Screening differential circular RNA expression profiles reveals the regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 pathway in bladder carcinoma , 2016, Scientific Reports.

[7]  Xiaohong Lv,et al.  MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer , 2016, International journal of oncology.

[8]  Wei Zhang,et al.  MicroRNA Signaling Pathway Network in Pancreatic Ductal Adenocarcinoma. , 2015, Journal of genetics and genomics = Yi chuan xue bao.

[9]  Yu Zhang,et al.  c-Myc-activated long non-coding RNA H19 downregulates miR-107 and promotes cell cycle progression of non-small cell lung cancer. , 2015, International journal of clinical and experimental pathology.

[10]  Z. Aktary,et al.  A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity , 2015, Nature Communications.

[11]  Long Hua,et al.  miR-107 promotes hepatocellular carcinoma cell proliferation by targeting Axin2. , 2015, International journal of clinical and experimental pathology.

[12]  Ye Zhang,et al.  miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1 , 2015, Tumor Biology.

[13]  Na Han,et al.  miR-107 Activates ATR/Chk1 Pathway and Suppress Cervical Cancer Invasion by Targeting MCL1 , 2014, PloS one.

[14]  Z. Hao,et al.  CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition. , 2014, Urologic oncology.

[15]  Z. Wang,et al.  MicroRNA-103 Promotes Colorectal Cancer by Targeting Tumor Suppressor DICER and PTEN , 2014, International journal of molecular sciences.

[16]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[17]  N. Simone,et al.  MicroRNA-203 regulates caveolin-1 in breast tissue during caloric restriction , 2012, Cell cycle.

[18]  M. Zavolan,et al.  MicroRNAs 103 and 107 regulate insulin sensitivity , 2011, Nature.

[19]  Xin Lu,et al.  Epithelial cell polarity: a major gatekeeper against cancer? , 2011, Cell Death and Differentiation.

[20]  O. De Wever,et al.  Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[21]  T. Fujii,et al.  Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. , 2008, Cancer research.

[22]  E. Miska,et al.  MicroRNA—implications for cancer , 2007, Virchows Archiv.

[23]  M. Korc,et al.  Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. , 2007, The American journal of pathology.

[24]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[25]  S. Gallinger,et al.  Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. , 2004, Journal of the American College of Surgeons.

[26]  K. Lillemoe,et al.  Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators , 2000, Journal of Gastrointestinal Surgery.

[27]  K. Lillemoe,et al.  Resected adenocarcinoma of the pancreas - 616 patients: Results, outcome and prognostic indicators , 2000 .